Application of Remimazolam, Dexmedetomidine, and Esketamine in Pediatric Preoperative Sedation
A Comparative Study of the Application of Remimazolam, Dexmedetomidine, and Esketamine in Pediatric Preoperative Sedation
Maternal and Child Health Hospital of Hubei Province
150 participants
Apr 1, 2025
INTERVENTIONAL
Conditions
Summary
By comparing the application effects of three drugs in pediatric preoperative sedation, this study explores the optimal medication regimen, aiming to provide safer, more effective, and more personalized medication options for pediatric preoperative sedation. Additionally, this research will also focus on the impact of these three drugs on postoperative agitation in children, offering valuable references for the overall management of pediatric surgical anesthesia.
Eligibility
Inclusion Criteria3
- Children aged 2 to 5 years old
- the American Society of Anesthesiologists (ASA) physical status of Class I
- scheduled for adenotonsillectomy under general anesthesia, will be included.
Exclusion Criteria4
- Abnormal lung function and respiratory system function
- airway obstruction or deformity, history of mental illness
- electrocardiogram indicating bradycardia
- history of cardiac disease
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
remimazolam is administered intravenously at a dose of 0.3 mg/kg
dexmedetomidine is administered intravenously at a dose of 1 μg/kg
esketamine is administered intravenously at a dose of 0.5 mg/kg
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07050212